№ files_lp_4_process_1_27694
File format: docx
Character count: 3742
File size: 11 KB
Official SEC filing documenting individual transactions and holdings of securities for a corporate officer, detailing acquisitions, dispositions, and vesting schedules of stock and derivative securities.
Year:
2026
Region / City:
Cambridge, MA, United States
Document Type:
SEC Form 4
Issuer:
Biogen Inc.
Reporting Person:
Adam Keeney
Position:
Head of Corporate Development
Transaction Dates:
02/06/2026
Securities Involved:
Common Stock, Restricted Stock Units
Filing Date:
02/10/2026
Form Purpose:
Reporting changes in beneficial ownership under Section 16(a) of the Securities Exchange Act of 1934
Signature:
Wendell Taylor, attorney-in-fact
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2017
Region / City:
Australia
Subject:
Spinal Muscular Atrophy (SMA) Treatment
Document Type:
Clinical Submission
Organ / Institution:
Biogen Australia Pty Ltd
Author:
Biogen Australia Pty Ltd
Target Audience:
Healthcare Professionals, Regulatory Authorities
Period of Validity:
Ongoing (from 2017 onwards)
Approval Date:
2 November 2017
Date of Changes:
July 2020
Background:
TGA registered
Registration Status:
TGA registration for SMA treatment
Previous Consideration:
PBAC submission history
Clinical Claim:
Nusinersen is superior for pre-symptomatic SMA treatment with 3 SMN2 copies
Contextual Description:
This document outlines a clinical resubmission requesting a Section 100 Authority Required listing for the pre-symptomatic treatment of SMA with nusinersen for individuals with 3 SMN2 copies, aged under 18 years.
Year:
2021
Category:
Category 4 Submission
Type of Document:
Submission for PBS Listing
Therapeutic Area:
Multiple Sclerosis
Indication:
Clinically definite relapsing-remitting multiple sclerosis
Medical Condition:
Multiple Sclerosis
Prescriber Type:
Medical Practitioners
Restriction Type:
Authority Required (Streamlined)
Prescribing Instructions:
To be initiated by neurologists, monitoring for signs of progressive multifocal leukoencephalopathy
Comparison:
Natalizumab IV, Ofatumumab
Status:
Approved for listing
Clinical Trials:
REFINE, DELIVER
Treatment Duration:
Ongoing monitoring
Approval:
Therapeutic Goods Administration (TGA) approval on 7 December 2021
Public/Private:
Both Public and Private
Available Brands:
Tysabri
Method of Administration:
Subcutaneous injection
Intended Use:
Subcutaneous administration of natalizumab for multiple sclerosis
Safety Warnings:
Risk of progressive multifocal leukoencephalopathy
Year:
2021
Region / City:
Australia
Topic:
Pharmaceutical regulation and prescribing requirements
Document Type:
Regulatory submission
Organization:
Biogen Australia Pty Ltd
Author:
Biogen Australia Pty Ltd
Target Audience:
Medical practitioners, healthcare professionals
Action Period:
2021-2022
Approval Date:
31 August 2020
Modification Date:
7 September 2021
Status:
Approved by TGA
Context:
This is a regulatory submission regarding changes to the prescribing instructions for natalizumab (Tysabri®) under the PBS, specifically the removal of mandatory registration with the Tysabri Australian Prescribing Program.
Year:
2018
Region / City:
Maine
Theme:
Environmental Protection
Document Type:
Legal Regulation
Organization / Institution:
Department of Environmental Protection
Author:
Department of Environmental Protection
Target Audience:
Industry professionals, environmental engineers, waste management professionals
Period of Effect:
Ongoing
Approval Date:
July 8, 2018
Date of Changes:
July 8, 2018
Year:
2013
Region / city:
India
Theme:
Corporate governance, Shareholding
Document type:
Form
Organization / institution:
Government of India
Author:
Ministry of Corporate Affairs
Target audience:
Shareholders, companies
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Note:
Year
Theme:
Financial Crime Prevention
Document Type:
Certification Form
Target Audience:
Individuals opening accounts on behalf of legal entities
Year:
2024
Region / city:
Australia
Topic:
Beneficial ownership reform
Document type:
Consultation Paper
Author:
Australian Government, Treasury
Target audience:
Legal professionals, policymakers, corporations
Period of validity:
Ongoing
Approval date:
Not specified
Date of amendments:
Not specified
Note:
Year
Theme:
Beneficial Ownership and Control Regulations
Document Type:
Regulatory Notice
Organ / Institution:
ADGM
Target Audience:
ADGM registered entities, shareholders, and nominees
Year:
Not specified
Region / City:
ADGM
Topic:
Beneficial Ownership and Control
Document Type:
Regulatory Requirement
Organ / Institution:
ADGM
Author:
Not specified
Target Audience:
ADGM persons, registered entities, nominees
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2022
Region / city:
Global
Topic:
Beneficial Ownership Disclosure
Document Type:
Policy / Guideline
Institution:
World Bank
Author:
World Bank
Target Audience:
Procurement officials, Bidders, Consultants
Effective Date:
July 1, 2022
Approval Date:
November 1, 2017
Date of Changes:
Ongoing updates based on procurement regulations
Document Scope:
Investment Project Financing
Procurement Type:
Open or Limited International Competition
Decision Review:
After November 1, 2017
Declaration by the beneficial owner who holds or acquires significant beneficial ownership in shares
Year:
2013
Note:
Region / city
Subject:
Declaration of Significant Beneficial Ownership
Document type:
Form
Year:
2025
Region / City:
Milwaukee, WI
Subject:
Securities and Exchange Reporting
Document Type:
Regulatory Filing
Organization / Institution:
U.S. Securities and Exchange Commission
Author:
Charlotte Yarkoni
Target Audience:
Reporting Entities, Securities Regulators
Period of Effectiveness:
June 30, 2025
Approval Date:
N/A
Amendment Date:
N/A
Country:
United States
Issuing authority:
United States Securities and Exchange Commission
Form number:
4
OMB Number:
3235-0287
Legal basis:
Section 16(a) of the Securities Exchange Act of 1934; Section 30(h) of the Investment Company Act of 1940
Type of document:
Regulatory filing
Reporting person:
Garland J. Scott
Issuer:
ALX ONCOLOGY HOLDINGS INC
Ticker symbol:
ALXO
Issuer address:
323 Allerton Avenue, South San Francisco, CA 94080
Date of earliest transaction:
01/20/2026
Date signed:
01/21/2026
Derivative security:
Stock option (right to buy)
Exercise price:
$1.32
Number of shares underlying derivative security:
40,400
Expiration date:
01/19/2036
Vesting terms:
12 equal monthly installments beginning on February 20, 2026
Form:
SEC Form 4
Title:
Statement of Changes in Beneficial Ownership
Filing Authority:
United States Securities and Exchange Commission
Legal Basis:
Section 16(a) of the Securities Exchange Act of 1934; Section 30(h) of the Investment Company Act of 1940
OMB Number:
3235-0287
Reporting Person:
Alana K. Knowles
Reporting Person Address:
5001 Executive Parkway, Suite 200, San Ramon, CA 94583
Issuer:
Chevron Corp
Ticker Symbol:
CVX
Relationship to Issuer:
Officer (Controller)
Date of Earliest Transaction:
January 5, 2026
Date of Signature:
January 7, 2026
Securities Reported:
Common Stock; Non-Qualified Stock Option (Right to Buy)
Transaction Codes:
M (Exercise of Option); S (Sale)
Rule 10b5-1 Plan:
Trading plan adopted February 21, 2025
Signature:
Rose Z. Pierson, Attorney-in-Fact for Alana K. Knowles
Year:
2026
Region / City:
Washington, D.C.
Subject:
Securities and Exchange
Document Type:
SEC Form
Organization:
United States Securities and Exchange Commission
Author:
N/A
Target Audience:
Financial professionals, investors, and regulatory bodies
Period of Action:
2026
Date of Approval:
N/A
Date of Changes:
N/A
Contextual Description:
This official document provides a report on changes in beneficial ownership of securities filed with the SEC under Section 16(a) of the Securities Exchange Act of 1934.
Year:
2007
Region / City:
Washington, D.C.
Subject:
Securities and Exchange Commission, beneficial ownership changes
Document Type:
Legal form
Institution:
United States Securities and Exchange Commission
Author:
United States Securities and Exchange Commission
Target Audience:
Individuals involved in securities transactions
Period of Effectiveness:
From 06/01/2007
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / City:
Washington, D.C.
Topic:
Securities and Exchange
Document Type:
Regulatory filing
Organization / Institution:
United States Securities and Exchange Commission
Author:
Tingley Whittemore
Target Audience:
SEC, investors, corporate entities
Effective Period:
02/16/2024
Approval Date:
02/16/2024
Date of Changes:
02/16/2024
Year:
2026
Region / City:
Washington, D.C.
Subject:
Securities and Exchange
Document Type:
SEC Form
Issuer:
Keenova Therapeutics plc
Target Audience:
Reporting Person, SEC Filers
Effective Period:
01/01/2026
Approval Date:
01/01/2026
Amendment Date:
N/A
Date of Filing:
01/05/2026
Description:
A document filed with the U.S. Securities and Exchange Commission detailing changes in beneficial ownership, including securities acquired, disposed of, or owned by the reporting person.
Note:
Year
Region / City:
Wisconsin
Theme:
Flammable Liquid Storage Tanks, Ownership Change
Document Type:
Form
Organization / Institution:
Wisconsin Department of Agriculture, Trade and Consumer Protection, Division of Trade and Consumer Protection, Bureau of Weights and Measures
Author:
Wisconsin Department of Agriculture, Trade and Consumer Protection
Target Audience:
Tank Owners, Facility Operators
Period of Validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A